150 Chapter 4 Supplemental Table 3. Continued No dexamethasone-induced sleep problems (ΔSDSC<7) Median (IQR) or n (%) Candidate SNP AHSG rs4918 n = 43 Additive model (Alternate allele dosage C>G) 0.980 (0.960-1.932) Dominant risk allele GG 5 (11.6) GC+CC 38 (88.4) Recessive risk allele GG+GC 29 (67.4) CC 14 (32.6) Numbers are depicted as median (interquartile range) or number (%). Bold values are regarded as statistically significant with a p-value <0.20 and were subsequently included in multivariable analyses. Bold underlined values are statistically significant with a p-value <0.05. 1 One patient with BPDCN was excluded from this analysis 2 Patients with CNS involvement (defined as CNS-3 or other CNS manifestations at diagnosis, or TLP+) receive 2 additional intrathecal therapy administrations and are considered as “CNS involvement yes”. MRG patients without CNS involvement receive 13 intrathecal administrations, with CNS involvement 15.
RkJQdWJsaXNoZXIy MTk4NDMw